Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$185.68 USD

185.68
1,137,205

+0.90 (0.49%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $185.63 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122

Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's

Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study

Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.

Cassava (SAVA) Up on Progress With Alzheimers Disease Study

Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.

Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far

Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.

Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.

The Zacks Analyst Blog Highlights Exxon Mobil, Costco Wholesale, Activision Blizzard, Biogen and Arista Networks

Exxon Mobil, Costco Wholesale, Activision Blizzard, Biogen and Arista Networks are part of the Zacks top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Exxon Mobil, Costco & Activision Blizzard

Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Costco Wholesale Corporation (COST), and Activision Blizzard, Inc. (ATVI).

Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match

Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.

The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio

Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.

Ekta Bagri headshot

Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates

Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.

Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs

Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.

Biogen Inc. (BIIB) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?

Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $275.25, marking a -0.75% move from the previous day.

Novavax (NVAX) Down 2.9% Since Last Earnings Report: Can It Rebound?

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

Biogen Inc. (BIIB) closed at $274.01 in the latest trading session, marking a +1.39% move from the prior day.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI